Cidara Therapeutics Inc.
Cidara Therapeutics Reports Q1 2024 Financial Results and Key Corporate Updates
Summary
Cidara Therapeutics, Inc. reported its financial results for the first quarter of 2024, revealing a net loss of $10.3 million compared to a net income of $3.0 million in the same period of 2023. The company also disclosed a significant private placement of $240 million, reacquired exclusive global development and commercial rights to CD388, and divested the rezafungin program. Recent highlights include a 1-for-20 reverse stock split, new board appointments, and presentations at major medical conferences. Total revenue for Q1 2024 was $8.5 million, primarily driven by milestone achievement, ongoing R&D services, and royalty revenue.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement